Submitted:
10 October 2023
Posted:
10 October 2023
You are already at the latest version
Abstract

Keywords:
1. Background
2. Materials and Methods
3. Results
Linear sequence similarity analysis
Similarity analysis of TCR-mediated recognition
4. Discussion
Supplementary Materials
Authors Contributions
Funding support
Ethics approval and consent to participate
Consent for publication
Data availability
Acknowledgments
References
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng J Med 366, 2443–2454, 2012. [CrossRef]
- Brahmer JR, Tykodi SS, Chow LQ, Hwu W-J, Topalian SL, Hwu P, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Eng J Med 366: 2455–2465, 2012. [CrossRef]
- CH June, RS O’Conner, OU Kawalelenet., S Ghassemi MC, Milone DOI: CAR T cell immunotherapy for human cancer. Science 2018, 359. 1361-1365. [CrossRef]
- JP.Manis, DE. Furst, JS.Tirnauer, and AM.Feldweg: https://www.update.com/contents/overview of therapeutic monoclonal antibodies.
- Ayelet Sivan, Leticia Corrales, Nathaniel Hubert, Jason B. Williams, Keston Aquino-Michaels et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science 2015, 350, 1084-1089. [CrossRef]
- L.Zitogel, M.Ayyoub, B.Routy, and G.Kroemer. Microbiome and Anticancer Immunosurveillance. Cell. 165, 2016, 276-287. [CrossRef]
- T.Mitsuoka, Bifidobacteria and their role in human health. J Indust Microbiol 6:263-268 Journal of Industrial Microbiology, Volume 6, Issue 4, 1 December 1990, Pages 263–267. [CrossRef]
- Matsueda S, Komatsu N, Kusumoto K, Koga S, Yamada A, Kuromatsu R, et al. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: a new biomarker for overall survival of patients with malignant diseases. Dev Comp Immunol. 2013;41(1):68-76. [CrossRef]
- Matsueda S, Itoh K, Shichijo S. Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte-specific protein tyrosine kinase. Cancer Sci. 2018 Mar;109(3):611-617. [CrossRef]
- C.Szeto, CA.Lobes, AT.Nguyen, and S.Gras, TCR recognition of Peptide-MHC-I: Rule Markers and Breakers. Int. J. Mol. Sci.2021 22, 68. [CrossRef]
- Harashima N. Tanaka K, Sasatomi T, Locoregional Y, Miyagi Y, Yamada A, Tamura M, Yamana Y, Itoh K Shichijo S. Recognition of the Lck tyrosine kinase as a tumor antigen by T cells of metastatic cancer patients. Eur J Immunol 31:323-332, 2001. [CrossRef]
- LF.Su, BA.Kidd, A.Han. JJ.Kotzin, and MM. Davis. 2013. Virus-specific CD4(+)memory-phenotype T cells are abundant 9n unexposed adults. Immunity 38,373-383. [CrossRef]



Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).